Writing in 2017, Aetion's co-founder and president Jeremy Rassen discusses how the 21st Century Cures Act and forthcoming Prescription Drug User Fee Act (PDUFA) VI are reshaping the regulatory landscape, accelerating the integration of real-world data (RWD) into decision-making processes in healthcare, and offering faster, more cost-effective alternatives to randomized controlled trials (RCTs) through rapid-cycle analytics technology, which could revolutionize evidence generation and decision-making in patient care.
Read More
Read More